Valneva Stock Quote VLA - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

3.276

Bid

3.25

Ask

3.288

Volume

193,891

3.21 Day's Range 3.288

2.95 52 Week Range 7.168

Market Cap

452.75M

Previous Close

3.25

Open

3.26

Last Trade

3.276

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

570,518

Shares Outstanding

138,202,132

Dividend Yield

PE Ratio

-4.47

Earnings Per Share (EPS)

-0.73

Revenue

175.73M

Net Profit

-101.43M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.valneva.com

Headquarters

Saint-herblain, Loire-atlantique, Fra

Founded

1970

Valneva SE is listed in the Pharmaceutical Preparations sector of the Euronext with ticker VLA. The last closing price for Valneva was 3.25 €. Over the last year, Valneva shares have traded in a share price range of 2.95 € to 7.168 €.

Valneva currently has 138,202,132 shares outstanding. The market capitalization of Valneva is 449.16 € million. Valneva has a price to earnings ratio (PE ratio) of -4.47.

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®Funding will support clinical trials in vulnerable groups, such as children...

CEPI renforce son partenariat avec Valneva en lui octroyant un nouveau financement de $41,3 millions visant à accroître l’accessibilité du premier vaccin au monde contre le chikungunya

CEPI renforce son partenariat avec Valneva en lui octroyant un nouveau financement de $41,3 millions visant à accroître l’accessibilité du premier vaccin au monde contre le chikungunya Valneva...

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Participants completed primary vaccination series (3 doses) with VLA15Primary vaccination series to be followed by a booster approximately one year after completion New York, NY and...

Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants

Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants Les participants à l’essai ont reçu les trois doses de VLA15 de la...

Declaration of shares and voting rights - Valneva SE - June 30, 2024

Declaration of shares and voting rights - Valneva SE - June 30, 2024 VALNEVA Declaration of shares and voting rights June 30, 2024______________________________________________________________...

Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024

Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024 VALNEVA Déclaration d’actions et de droits de vote 30 juin 2024__________________________________________________________...

Valneva reçoit une autorisation de mise sur le marché en Europe pour le premier vaccin au monde contre le chikungunya, IXCHIQ®

Valneva reçoit une autorisation de mise sur le marché en Europe pour le premier vaccin au monde contre le chikungunya, IXCHIQ® Saint Herblain (France), le 1 juillet 2024 – Valneva SE (Nasdaq...

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

Saint-Herblain (France), June 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors...

Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale et la nomination d’un nouvel administrateur à son conseil d’administration

Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale et la nomination d’un nouvel administrateur à son conseil d’administration Saint-Herblain (France), le 26...

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® Saint-Herblain (France), June 24, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.166	-4.82277745497	3.442	3.5	3.204	327181	3.32682207	DE
4	0.036	1.11111111111	3.24	3.54	3.114	372506	3.32001395	DE
12	-0.124	-3.64705882353	3.4	4.298	3.104	570518	3.61269871	DE
26	-0.42	-11.3636363636	3.696	4.298	2.95	542733	3.57262166	DE
52	-3.394	-50.8845577211	6.67	7.168	2.95	439651	4.30099046	DE
156	-8.684	-72.6086956522	11.96	29.7	2.95	747038	12.62533634	DE
260	0.146	4.66453674121	3.13	29.7	1.784	644408	11.38222616	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M